Latest News & Features
Big Pharma
Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details. 19 March 2024
Biotechnology
It is critical that the emerging field of personalised medicine receives appropriate patent protection, explain Joel Coles and Theo Cooper of Powell Gilbert. 14 March 2024
CRISPR
Japanese imaging and electronics firm has acquired non-exclusive licence from ERS Genomics | Technology will be used by Elixirgen Scientific, acquired by Ricoh in 2022. 14 March 2024
Big Pharma
Pharma company’s new partnership is an “opportunity” to accelerate access and maximise the potential of AstraZenica’s asthma drug | Delhi-based pharma firm will provide valuable distribution channels. 12 March 2024
Big Pharma
Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes. 12 March 2024
Unified Patent Court
Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert. 7 March 2024
Big Pharma
WTO members failed to reach consensus on whether to expand patent waiver agreed in 2022 | Extended proposal would include tests and treatments for COVID-19. 7 March 2024
Careers
‘Creative litigation strategist’ will expand firm’s capacity in complex technology areas | New hire joins from LTL Attorneys and spent much of career at Quinn Emanuel. 7 March 2024
Careers
Firm hires former Food and Drug Administration staffer from King & Spalding | Washington DC office gains nearly a decade of FDA experience. 5 March 2024
Medtech
The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin and Pete Conley from Know Labs to explore its impact on patent strategy and the changing face of medtech. 5 March 2024